1 – 92 of 92
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.
(
- Contribution to journal › Article
-
Mark
Risk of male breast cancer in users of testosterone 5a reductase inhibitors
2016) 2016 Annual Meeting of the American Society of Clinical Oncology In Journal of Clinical Oncology 34(Suppl 15).(
- Contribution to journal › Published meeting abstract
- 2015
-
Mark
Stable Peptide of the Endogenous Opioid Enkephalin Precursor and Breast Cancer Risk.
(
- Contribution to journal › Article
-
Mark
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation.
(
- Contribution to journal › Article
-
Mark
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
(
- Contribution to journal › Article
-
Mark
Ewing Sarcoma: Current Management and Future Approaches Through Collaboration.
(
- Contribution to journal › Scientific review
-
Mark
Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study.
(
- Contribution to journal › Article
- 2014
-
Mark
Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial.
(
- Contribution to journal › Article
-
Mark
t(14;18) Translocation: A Predictive Blood Biomarker for Follicular Lymphoma
(
- Contribution to journal › Article
-
Mark
Effect of Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma in Situ: 20 Years Follow-Up in the Randomized SweDCIS Trial.
(
- Contribution to journal › Article
-
Mark
Collection and Use of Family History in Oncology Clinics.
(
- Contribution to journal › Letter
-
Mark
Later stage at diagnosis and worse survival in cutaneous malignant melanoma among men living alone: a nationwide population-based study from sweden.
(
- Contribution to journal › Article
-
Mark
Emergence of New ALK Mutations at Relapse of Neuroblastoma.
(
- Contribution to journal › Article
-
Mark
Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome?
(
- Contribution to journal › Letter
- 2013
-
Mark
Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
(
- Contribution to journal › Article
-
Mark
90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial.
(
- Contribution to journal › Article
-
Mark
Communication and Trust in the Care Provided to a Dying Parent: A Nationwide Study of Cancer-Bereaved Youths.
2013) In Journal of Clinical Oncology(
- Contribution to journal › Article
-
Mark
International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma-Related Bone Disease.
(
- Contribution to journal › Article
-
Mark
Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity.
(
- Contribution to journal › Article
-
Mark
Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis.
(
- Contribution to journal › Article
-
Mark
Evaluation of Human Papillomavirus Antibodies and Risk of Subsequent Head and Neck Cancer.
(
- Contribution to journal › Article
- 2012
-
Mark
Upfront Autologuos Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01.
(
- Contribution to journal › Article
-
Mark
Prostate Cancer Screening: Facts, Statistics, and Interpretation in Response to the US Preventive Services Task Force Review
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Is Family History Associated With Improved Survival in Patients With Gastric Cancer?
(
- Contribution to journal › Article
-
Mark
Absolute Risk Prediction of Second Primary Thyroid Cancer Among 5-Year Survivors of Childhood Cancer.
2012) In Journal of Clinical Oncology(
- Contribution to journal › Article
-
Mark
Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study.
(
- Contribution to journal › Article
-
Mark
FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone as First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer.
(
- Contribution to journal › Article
-
Mark
Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer.
(
- Contribution to journal › Article
-
Mark
Impact of Cigarette Smoking on Cancer Risk in the European Prospective Investigation into Cancer and Nutrition Study.
2012) In Journal of Clinical Oncology(
- Contribution to journal › Article
- 2011
-
Mark
Management of Seminomatous Testicular Cancer: A Binational Prospective Population-Based Study From the Swedish Norwegian Testicular Cancer Study Group (SWENOTECA).
(
- Contribution to journal › Article
-
Mark
Challenges to the Development of New Agents for Molecularly Defined Patient Subsets: Lessons From BRCA1/2-Associated Breast Cancer
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Immunotherapy for Glioblastoma: The Devil Is in the Details Reply
(
- Contribution to journal › Letter
-
Mark
Response-Guided Induction Therapy in Pediatric Acute Myeloid Leukemia With Excellent Remission Rate.
(
- Contribution to journal › Article
-
Mark
Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008.
(
- Contribution to journal › Article
-
Mark
Familial Mortality and Familial Incidence in Cancer.
(
- Contribution to journal › Article
-
Mark
Familial risks in cancer of unknown primary: tracking the primary sites.
(
- Contribution to journal › Article
-
Mark
Population-Based Study of Treatment Guided by Tumor Marker Decline in Patients With Metastatic Nonseminomatous Germ Cell Tumor: A Report From the Swedish-Norwegian Testicular Cancer Group.
(
- Contribution to journal › Article
-
Mark
Digoxin use and the risk of breast cancer in women
(
- Contribution to journal › Article
- 2010
-
Mark
Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based Study.
(
- Contribution to journal › Article
-
Mark
Population-Based Study of the Risk of Second Primary Contralateral Breast Cancer Associated With Carrying a Mutation in BRCA1 or BRCA2.
(
- Contribution to journal › Article
-
Mark
Reducing Unnecessary Biopsy During Prostate Cancer Screening Using a Four-Kallikrein Panel: An Independent Replication.
(
- Contribution to journal › Article
-
Mark
Absolute and Relative Risk of Cardiovascular Disease in Men With Prostate Cancer: Results From the Population-Based PCBaSe Sweden.
(
- Contribution to journal › Article
-
Mark
Improving Surveillance and Quality of Life of BRCA Mutation Carriers.
(
- Contribution to journal › Article
-
Mark
Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma.
(
- Contribution to journal › Article
-
Mark
Identification of Subtypes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Reveals a Gene Signature Prognostic of Outcome.
(
- Contribution to journal › Article
-
Mark
Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 Trial.
(
- Contribution to journal › Article
-
Mark
Genomic Changes in Chromosomes 10, 16, and X in Malignant Peripheral Nerve Sheath Tumors Identify a High-Risk Patient Group.
(
- Contribution to journal › Article
- 2009
-
Mark
Individualized intensification of treatment based on tumor marker decline in metastatic nonseminomatous germ cell testicular cancer (NSGCT): A report from the Swedish Norwegian Testicular Cancer Group, SWENOTECA
2009) 45th Annual Meeting of the American-Society-of-Clinical-Oncology In Journal of Clinical Oncology 27(15).(
- Contribution to journal › Published meeting abstract
-
Mark
A European treatment protocol for bone sarcoma in patients older than 40 years
2009) 45th Annual Meeting of the American-Society-of-Clinical-Oncology In Journal of Clinical Oncology 27(15).(
- Contribution to journal › Published meeting abstract
-
Mark
Updated analysis of a phase II study (20060314) of panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC)
2009) 45th Annual Meeting of the American-Society-of-Clinical-Oncology In Journal of Clinical Oncology 27(15).(
- Contribution to journal › Published meeting abstract
-
Mark
Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia.
(
- Contribution to journal › Article
-
Mark
Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma.
(
- Contribution to journal › Article
-
Mark
Influence on the Health of the Partner Affected by Tumor Disease in the Wife or Husband Based on a Population-Based Register Study of Cancer in Sweden.
(
- Contribution to journal › Article
-
Mark
Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy.
(
- Contribution to journal › Article
-
Mark
Risk-Adapted Treatment in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: The SWENOTECA Management Program.
(
- Contribution to journal › Article
-
Mark
Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
(
- Contribution to journal › Article
-
Mark
Role for Genetic Anticipation in Lynch Syndrome.
(
- Contribution to journal › Article
- 2008
-
Mark
Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma
(
- Contribution to journal › Article
-
Mark
Long-term prediction of prostate cancer: Prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population
(
- Contribution to journal › Article
-
Mark
Pitfalls of CA-125 levels in the preoperative work-up of ovarian masses - Reply
(
- Contribution to journal › Letter
-
Mark
Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: A Randomized phase III trial
(
- Contribution to journal › Article
-
Mark
Absolute Risk Reductions for Local Recurrence After Postoperative Radiotherapy After Sector Resection for Ductal Carcinoma In Situ of the Breast.
(
- Contribution to journal › Article
-
Mark
Functional Diffusion map (fDM) as an early imaging biomarker for high grade glioma: Correlation with conventional radiographic response and overall survival.
(
- Contribution to journal › Article
- 2007
-
Mark
Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor - Positive premenopausal breast cancer
(
- Contribution to journal › Article
-
Mark
Suicide among survivors of childhood cancer
(
- Contribution to journal › Letter
-
Mark
Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: A report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group
(
- Contribution to journal › Article
-
Mark
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
(
- Contribution to journal › Article
-
Mark
Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors
(
- Contribution to journal › Article
-
Mark
Measurements of proteases or protease system components in blood to enhance prediction of disease risk or outcome in possible cancer
(
- Contribution to journal › Article
- 2006
-
Mark
Pathways through relapses and deaths of children with acute lymphoblastic leukemia: Role of allogeneic stem-cell transplantation in Nordic data
(
- Contribution to journal › Article
-
Mark
Prognostic significance of chromosome aberrations in high-grade soft tissue sarcomas
(
- Contribution to journal › Article
-
Mark
Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition
(
- Contribution to journal › Article
-
Mark
Topoisomerase II{alpha} Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in HER-2/neu-Amplified Breast Cancer: Scandinavian Breast Group Trial 9401.
(
- Contribution to journal › Article
-
Mark
Physiological and Metabolic MR Imaging in gliomas
(
- Contribution to journal › Article
- 2005
-
Mark
Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: A multicenter study by the International Ovarian Tumor Analysis Group
(
- Contribution to journal › Article
-
Mark
Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: A joint study by the Italian and Scandinavian Sarcoma Groups
(
- Contribution to journal › Article
-
Mark
Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401.
(
- Contribution to journal › Published meeting abstract
-
Mark
Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
(
- Contribution to journal › Article
-
Mark
International Staging System for Multiple Myeloma.
(
- Contribution to journal › Article
-
Mark
Childhood cancer survival trends in Europe: a EUROCARE Working Group study
(
- Contribution to journal › Article
- 2004
-
Mark
Tumor karyotype predicts clinical outcome in colorectal cancer patients
(
- Contribution to journal › Article
- 2003
-
Mark
Altered expression of MLH1, MSH2, and MSH6 in predisposition to hereditary nonpolyposis colorectal cancer
(
- Contribution to journal › Article
-
Mark
Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome
(
- Contribution to journal › Article
- 2002
-
Mark
Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma
(
- Contribution to journal › Article
-
Mark
Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis
(
- Contribution to journal › Article
-
Mark
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types
(
- Contribution to journal › Article
- 2001
-
Mark
S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer
(
- Contribution to journal › Article
-
Mark
Quality of life in palliative cancer care: results from a cluster randomized trial
(
- Contribution to journal › Article
-
Mark
Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries
(
- Contribution to journal › Article
-
Mark
Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification
(
- Contribution to journal › Article
- 1999
-
Mark
Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35
(
- Contribution to journal › Article
- 1990
-
Mark
Cellular DNA content and prognosis of high-grade soft tissue sarcoma: the Scandinavian Sarcoma Group experience
(
- Contribution to journal › Article